Peter Clark to Antineoplastic Agents
This is a "connection" page, showing publications Peter Clark has written about Antineoplastic Agents.
Connection Strength
2.194
-
Clark PE, Spiess PE, Agarwal N, Bangs R, Boorjian SA, Buyyounouski MK, Efstathiou JA, Flaig TW, Friedlander T, Greenberg RE, Guru KA, Hahn N, Herr HW, Hoimes C, Inman BA, Kader AK, Kibel AS, Kuzel TM, Lele SM, Meeks JJ, Michalski J, Montgomery JS, Pagliaro LC, Pal SK, Patterson A, Petrylak D, Plimack ER, Pohar KS, Porter MP, Sexton WJ, Siefker-Radtke AO, Sonpavde G, Tward J, Wile G, Dwyer MA, Smith C. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J Natl Compr Canc Netw. 2016 10; 14(10):1213-1224.
Score: 0.407
-
Eifler JB, Scarpato KR, Clark PE. Management of noninvasive bladder cancers. Curr Opin Oncol. 2015 May; 27(3):185-90.
Score: 0.369
-
Keegan KA, Resnick MJ, Clark PE. Multimodal therapies for muscle-invasive urothelial carcinoma of the bladder. Curr Opin Oncol. 2012 May; 24(3):278-83.
Score: 0.300
-
Clark PE. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int. 2009 Nov; 76(9):939-45.
Score: 0.248
-
Clark PE. Recent advances in targeted therapy for renal cell carcinoma. Curr Opin Urol. 2007 Sep; 17(5):331-6.
Score: 0.217
-
Clark PE, Streem SB. Endourologic management of upper tract transitional cell carcinoma. ScientificWorldJournal. 2004 Jun 07; 4 Suppl 1:62-75.
Score: 0.173
-
Clark PE. Urothelial carcinoma with squamous differentiation: response to chemotherapy and radiation. Urol Oncol. 2015 Oct; 33(10):434-6.
Score: 0.094
-
Bassett JC, Eifler JB, Resnick MJ, Clark PE. Developments and controversies in the management of noninvasive bladder cancer. Curr Opin Oncol. 2014 May; 26(3):299-304.
Score: 0.086
-
Morgan TM, Clark PE. Bladder cancer. Curr Opin Oncol. 2010 May; 22(3):242-9.
Score: 0.065
-
Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, Milani RV, Sagalowsky AI, Smith MR, Zakai N. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. CA Cancer J Clin. 2010 May-Jun; 60(3):194-201.
Score: 0.064
-
Barocas DA, Clark PE. Bladder cancer. Curr Opin Oncol. 2008 May; 20(3):307-14.
Score: 0.057
-
Clark PE. Bladder cancer. Curr Opin Oncol. 2007 May; 19(3):241-7.
Score: 0.053
-
Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021 Aug; 206(2):199-208.
Score: 0.035
-
Pal SK, Agarwal N, Boorjian SA, Hahn NM, Siefker-Radtke AO, Clark PE, Plimack ER. National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder Cancer. J Clin Oncol. 2016 09 20; 34(27):3346-8.
Score: 0.025